JP5671347B2 - アドレナリン受容体のα１ループ２またはβ２ループ１上のエピトープを認識する抗体に対して結合親和性を有するペプチド - Google Patents

アドレナリン受容体のα１ループ２またはβ２ループ１上のエピトープを認識する抗体に対して結合親和性を有するペプチド Download PDF

Info

Publication number
JP5671347B2
JP5671347B2 JP2010542631A JP2010542631A JP5671347B2 JP 5671347 B2 JP5671347 B2 JP 5671347B2 JP 2010542631 A JP2010542631 A JP 2010542631A JP 2010542631 A JP2010542631 A JP 2010542631A JP 5671347 B2 JP5671347 B2 JP 5671347B2
Authority
JP
Japan
Prior art keywords
peptide
solid phase
nucleic acid
loop
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010542631A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011518113A5 (https=
JP2011518113A (ja
Inventor
クンツェ、ルドルフ
ヴァルカト、ゲルト
ローゼンタール、ペーター
シュトラウベ、リヒャルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresenius Medical Care Deutschland GmbH
Original Assignee
Fresenius Medical Care Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Medical Care Deutschland GmbH filed Critical Fresenius Medical Care Deutschland GmbH
Publication of JP2011518113A publication Critical patent/JP2011518113A/ja
Publication of JP2011518113A5 publication Critical patent/JP2011518113A5/ja
Application granted granted Critical
Publication of JP5671347B2 publication Critical patent/JP5671347B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
    • B01J20/286—Phases chemically bonded to a substrate, e.g. to silica or to polymers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3244—Non-macromolecular compounds
    • B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
    • B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
    • B01J20/3251—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such comprising at least two different types of heteroatoms selected from nitrogen, oxygen or sulphur
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010542631A 2008-01-15 2009-01-15 アドレナリン受容体のα１ループ２またはβ２ループ１上のエピトープを認識する抗体に対して結合親和性を有するペプチド Expired - Fee Related JP5671347B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08100510A EP2080519A1 (en) 2008-01-15 2008-01-15 Peptides having binding affinity to an antibody which recognizes an epitope on an alpha1 loop 2 or beta 2 loop 1 of an adrenoreceptor
EP08100510.0 2008-01-15
PCT/EP2009/050446 WO2009090227A2 (en) 2008-01-15 2009-01-15 PEPTIDES HAVING BINDING AFFINITY TO AN ANTIBODY WHICH RECOGNIZES AN EPITOPE ON AN α1 LOOP 2 OR β2 LOOP 1 OF AN ADRENORECEPTOR

Publications (3)

Publication Number Publication Date
JP2011518113A JP2011518113A (ja) 2011-06-23
JP2011518113A5 JP2011518113A5 (https=) 2014-02-20
JP5671347B2 true JP5671347B2 (ja) 2015-02-18

Family

ID=39402559

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010542631A Expired - Fee Related JP5671347B2 (ja) 2008-01-15 2009-01-15 アドレナリン受容体のα１ループ２またはβ２ループ１上のエピトープを認識する抗体に対して結合親和性を有するペプチド

Country Status (5)

Country Link
US (2) US8455442B2 (https=)
EP (2) EP2080519A1 (https=)
JP (1) JP5671347B2 (https=)
ES (1) ES2639573T3 (https=)
WO (1) WO2009090227A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2497828A1 (en) 2011-03-07 2012-09-12 Charité - Universitätsmedizin Berlin Use of aptamers in therapy and/or diagnosis of autoimmune diseases
EP2742065B1 (en) * 2011-08-12 2017-08-02 E.R.D.E.-aak-Diagnostik Gmbh Agonistic autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in alzheimer's and vascular dementia
CN104428310A (zh) * 2012-06-26 2015-03-18 弗·哈夫曼-拉罗切有限公司 细胞穿透肽和鉴定细胞穿透肽的方法
JP2017515799A (ja) * 2014-04-03 2017-06-15 オウ テルヴィスリク ピーマ バイオテウノロジーテ アレンダスケスクス コレステロール低下剤およびクロストリジウム・ディフィシレに対する抗微生物剤としてのラクトバチルス・プランタルムＩｎｄｕｃｉａ株ＤＳＭ２１３７９
CN120647762B (zh) * 2025-06-16 2026-01-23 首都医科大学附属北京友谊医院 一种抗β1-AR-ECII抗体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU677968B2 (en) * 1992-09-25 1997-05-15 H. Lundbeck A/S DNA encoding human alpha 1 adrenergic receptors and uses thereof
KR20020047177A (ko) * 1999-09-21 2002-06-21 아피나 이문테히닉 게엠베하 확장성 심근질환을 유발하는 자동항체를 제거하기 위한펩티드
ATE368688T1 (de) * 2000-11-08 2007-08-15 Fresenius Medical Care Affina Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
US6451547B1 (en) * 2001-04-25 2002-09-17 Syn X Pharma Process for differential diagnosis of Alzheimer's dementia and device therefor
US20020172676A1 (en) * 2001-05-16 2002-11-21 George Jackowski Method of treatment of alzheimer's disease and device therefor
AU2003293004A1 (en) * 2002-11-29 2004-06-23 Max-Delbruck-Centrum Fur Molekulare Medizin Identification of agonistic autoantibodies
JP2008537961A (ja) * 2005-04-15 2008-10-02 ボード、オブ、トラスティーズ、オブ、ミシガン、ステイト、ユニバーシティ Ｇｐｃｒモジュレーター
EP1832600A1 (en) * 2006-03-09 2007-09-12 Max-Delbrück-Centrum Für Molekulare Medizin Peptides against autoantibodies associated with glaucoma and use of these peptides
WO2008151847A1 (en) * 2007-06-13 2008-12-18 Max-Delbrück-Centrum für Molekulare Medizin Autoantibody binding peptides and their use for the treatment of vascular diseases
WO2009132283A2 (en) * 2008-04-24 2009-10-29 University Of Miami Method for treating autoimmune disorders
EP3093351B1 (en) * 2008-07-09 2018-04-18 Celera Corporation Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof

Also Published As

Publication number Publication date
EP2244718A2 (en) 2010-11-03
ES2639573T3 (es) 2017-10-27
US20130302292A1 (en) 2013-11-14
JP2011518113A (ja) 2011-06-23
US9574017B2 (en) 2017-02-21
US8455442B2 (en) 2013-06-04
WO2009090227A3 (en) 2010-02-04
US20110104226A1 (en) 2011-05-05
WO2009090227A2 (en) 2009-07-23
EP2244718B1 (en) 2017-06-07
EP2080519A1 (en) 2009-07-22

Similar Documents

Publication Publication Date Title
US10100100B2 (en) Metallothionein-derived peptide fragments
JP2000507828A (ja) アルツハイマー病の診断および治療法
JP5671347B2 (ja) アドレナリン受容体のα１ループ２またはβ２ループ１上のエピトープを認識する抗体に対して結合親和性を有するペプチド
US20090220469A1 (en) Peptides against autoantibodies associated with glaucoma and use of these peptides
CN109718363B (zh) 预防、缓解或治疗阿尔茨海默病的肽及其应用
JP2007526898A (ja) Ｌｐａを含む化合物
CN109134664B (zh) 一种经修饰的生长分化因子及其制备方法和应用
CN102504016B (zh) 淀粉样蛋白纤维性寡聚体构象型抗原表位多肽及其应用
CN104619333B (zh) 经修饰的肽，cb受体的配体，用于评估与cb受体结合的试剂盒、体外方法，用于调节cb受体活性的药物组合物、用途
EP1572168B1 (en) Anti-infarction molecules
Mruthinti et al. Autoimmunity in Alzheimer's disease as evidenced by plasma immunoreactivity against RAGE and Aβ42: complication of diabetes
Mruthinti et al. Relationship between the induction of RAGE cell-surface antigen and the expression of amyloid binding sites
US9708372B2 (en) Agonistic autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in Alzheimer's and vascular dementia
US20090081227A1 (en) Human and mammalian stem cell-derived neuron survival factors
JP6857854B2 (ja) サリューシン−β阻害剤のスクリーニング方法及びサリューシン−β阻害剤
WO2024122553A1 (ja) 潰瘍性大腸炎又は原発性硬化性胆管炎の治療方法
KR20250010632A (ko) 혈관신생 유도 제제
JPH0578391A (ja) ペプチドおよびその塩
HK1083202B (en) Anti-infarction molecules
TW201103559A (en) Anti sulfatides and anti sulfated proteoglycans antibodies and their use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130917

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20131217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140425

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140507

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140626

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141219

R150 Certificate of patent or registration of utility model

Ref document number: 5671347

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees